The European Commission and European Medicines Agency have approved the triple combination Kaftrio for use in certain cystic fibrosis patients, triggering the drug to be accessible on the UK’s National Health Service.
List view / Grid view
Filter the results
A new agreement will allow eligible cystic fibrosis patients in England to have access to CFTR modulators to treat the underlying cause of their disease.
The NHS is set to launch a new payment method for antibiotic development to incentivise pharmaceutical companies.
A CAR-T immunotherapy for adults with an aggressive form of non-Hodgkin lymphoma has been provisionally rejected by the NHS...
NHS England has announced a commercial agreement that allows patients in England immediate access to the innovative new multiple sclerosis treatment...
NICE has recommended sorafenib to be routinely available for patients on the NHS making it one of the 24 drugs appraised from the CDF...
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
25 September 2015 | By Victoria White
The British Generic Manufacturers Association, the Association of the British Pharmaceutical Industry (ABPI), and the UK BioIndustry Association (BIA) have joined forces to welcome NHS England’s new publication “What is a biosimilar medicine?”.